CLINUVEL PHARMACUTIC-SP ADR

CUVLNASDAQ

🏆 #2667 by market capEarnings Sep 1US Equity

$6.86▲ $0.12 (+1.78%)

Market closed · at close

1h—

24h▲ 1.8%

7d▲ 7.0%

14d▼ 2.0%

30d—

1y—

🏦Market Cap

$346M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $6.78 – $6.95
52-Week Range: $5.98 – $9.00
Volume: $3.84B
Avg Volume: $2.68B
Shares Outstanding: 50.4M
Next Earnings: Sep 29, 2026

Fundamentals Snapshot

Annual Revenue: $35M
Last Q Revenue: $9M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own CUVL

✓High-growth profile — revenue up +25.5% YoY with expanding US Equity exposure.
✓Healthy economics — 73% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$35M▲ +30.6% YoY

Gross Margin (TTM)

72.7%▲ +0.4% YoY

Operating Income (TTM)

$8M▲ +30.6% YoY

Free Cash Flow (TTM)

$3M▲ +30.6% YoY

About CLINUVEL PHARMACUTIC-SP ADR

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

🦦